Thermo Fisher Scientific, Inc.
TMO
$0.00
-0.62%
Thermo Fisher Scientific is a global leader in the healthcare sector, providing scientific instruments, laboratory equipment, diagnostics consumables, and life science reagents. The company operates as a dominant, integrated platform player across four key segments—analytical technologies, specialty diagnostics, life science solutions, and lab products & services—leveraging its scale and breadth to serve a vast customer base in research, clinical, and industrial markets. The current investor narrative centers on the company's post-pandemic normalization, as it transitions from the extraordinary COVID-19-related revenue surge to a more sustainable, yet still solid, organic growth trajectory, with recent financials and market attention focused on its ability to drive margin expansion and integrate strategic acquisitions in a moderating demand environment.…
TMO
Thermo Fisher Scientific, Inc.
$0.00
TMO 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Thermo Fisher Scientific, Inc.'s 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
13 analysts
Implied Upside
—
vs. current price
Analyst Count
13
covering this stock
Price Range
$0 - $0
Analyst target range
The stock is covered by 13 analysts, with recent institutional ratings showing a strong bullish bias, including actions like Citigroup upgrading from 'Neutral' to 'Buy' and Keybanc moving from 'Sector Weight' to 'Overweight' in late 2025. The consensus recommendation is a 'Buy', with an average target price implied by the estimated EPS of $36.24 and a forward PE of 18.27, which calculates to approximately $662, representing a potential upside of roughly 35% from the current price of $491.46, indicating significant bullish sentiment among covering firms. The target range, derived from estimated EPS lows and highs of $35.54 to $37.21, translates to a price range of approximately $649 to $680; the high end assumes successful execution on growth and margin initiatives, while the low end likely factors in potential macroeconomic headwinds or competitive pressures, with the relatively tight spread suggesting solid analyst conviction in the base-case outlook.
Bulls vs Bears: TMO Investment Factors
The evidence presents a classic battle between deteriorating price action and strong underlying fundamentals. The bear case is currently dominant in the near term, as the severe technical breakdown and valuation de-rating reflect real investor concerns about growth normalization and margin pressure. However, the bull case is supported by deep fundamental strength, significant analyst conviction, and a forward valuation that now appears reasonable. The single most important tension in the investment debate is whether the company's robust free cash flow generation and dominant market position can successfully navigate the post-pandemic transition and reignite earnings growth fast enough to arrest the technical decline and validate the still-premium valuation. The resolution of Q1 2026 margins and organic growth guidance will be pivotal.
Bullish
- Strong Analyst Conviction & Upside: Analysts are overwhelmingly bullish, with a consensus 'Buy' rating and an average target price of ~$662, implying 35% upside from the current price of $491.46. The target range is tight ($649-$680), indicating high conviction in the company's ability to execute on its growth and margin initiatives.
- Robust Fundamentals & Cash Flow: The company generates massive free cash flow ($6.29B TTM) and maintains a healthy balance sheet (Debt/Equity of 0.76, Current Ratio of 1.89). This provides significant financial flexibility for strategic M&A, dividends, and share buybacks, insulating the business during downturns.
- Attractive Forward Valuation: The forward P/E of 18.3x is a significant discount to the trailing P/E of 32.3x, reflecting market expectations for strong earnings growth. This forward multiple is reasonable for a market leader with 7.2% YoY revenue growth and a 16.2% net margin.
- Dominant, Diversified Market Position: As a global leader across four key healthcare segments, TMO benefits from scale, a broad product portfolio, and a recurring revenue base from consumables and services. This diversification mitigates risk from any single product or market slowdown.
Bearish
- Persistent Technical Downtrend: The stock is in a clear bearish phase, down 17.1% over three months and 9.5% over six months, with a -27.4% max drawdown. Negative momentum persists despite being oversold, indicating a lack of buyer conviction and potential for further downside.
- Valuation Premium & High Expectations: Even after the sell-off, the trailing P/E of 32.3x and P/S of 4.89x are at a premium to many healthcare peers and sit above the stock's own historical range. This premium valuation leaves little room for error and requires flawless execution to justify.
- Post-Pandemic Growth Normalization: Revenue growth has moderated to 7.2% YoY in Q4 2025 from pandemic-era peaks. The company faces the challenge of sustaining organic growth in a normalizing demand environment for diagnostics and research tools, which could pressure the premium multiple.
- Recent Gross Margin Compression: Q4 2025 gross margin compressed to 37.95% from 41.93% in Q3 2025, indicating potential cost pressures or an unfavorable product mix. Sustained margin pressure would directly threaten earnings growth and the company's ability to hit forward EPS estimates.
TMO Technical Analysis
The stock is in a pronounced downtrend, having declined 17.05% over the past three months and 9.55% over the last six months, significantly underperforming the broader market as indicated by a -13.05% relative strength over three months. With a current price of $491.46, the stock is trading at approximately 76% of its 52-week range ($385.46 to $643.99), positioning it closer to the lower bound and suggesting it may be approaching oversold territory, though the persistent negative momentum indicates it remains in a bearish phase. Recent momentum shows continued weakness, with the stock down 3.27% over the past month, which, while less severe than the three-month drop, still confirms the prevailing negative trend rather than signaling a reversal, especially given the stock's 1-year price change is a meager +0.49% against a strong market backdrop. Key technical support is clearly defined at the 52-week low of $385.46, while resistance sits at the 52-week high of $643.99; a sustained break below support would signal a deepening bearish trend, whereas a recovery above the recent downtrend line is needed for any bullish reversal. With a beta of 0.972, the stock exhibits market-like volatility, but its recent drawdown of -27.38% highlights significant idiosyncratic pressure, making risk management crucial despite its beta near 1.
Beta
0.97
0.97x market volatility
Max Drawdown
-27.4%
Largest decline past year
52-Week Range
$385-$644
Price range past year
Annual Return
+0.5%
Cumulative gain past year
| Period | TMO Return | S&P 500 |
|---|---|---|
| 1m | -3.3% | -2.5% |
| 3m | -17.1% | -4.6% |
| 6m | -9.5% | -2.0% |
| 1y | +0.5% | +29.8% |
| ytd | -17.1% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMO Fundamental Analysis
Revenue growth remains positive but has moderated from pandemic peaks, with Q4 2025 revenue of $12.215 billion representing a 7.2% year-over-year increase, continuing a trend of sequential quarterly revenue growth from $10.364 billion in Q1 to the Q4 figure. The company's profitability is robust, with Q4 2025 net income of $1.975 billion and a gross margin of 37.95%, though the gross margin has compressed slightly from 41.93% in Q3 2025, indicating some cost pressure or mix shift; the net margin for the quarter was a healthy 16.17%. The balance sheet and cash flow generation are strong, evidenced by a debt-to-equity ratio of 0.76, a current ratio of 1.89, and substantial trailing twelve-month free cash flow of $6.293 billion, providing ample liquidity and financial flexibility to fund operations, dividends, and strategic investments without excessive reliance on external financing.
Quarterly Revenue
$12.2B
2025-12
Revenue YoY Growth
+0.07%
YoY Comparison
Gross Margin
+0.37%
Latest Quarter
Free Cash Flow
$6.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMO Overvalued?
Given the company's consistent profitability, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio stands at 32.3x, while the forward PE is significantly lower at 18.3x, indicating the market expects substantial earnings growth in the coming year to justify the current price. Compared to sector averages, TMO's trailing PE of 32.3x and Price-to-Sales (PS) ratio of 4.89x likely trade at a premium to many healthcare equipment peers, a premium that may be justified by its market-leading position, diversified portfolio, and strong cash flow generation, but which also raises the bar for execution. Historically, the stock's current trailing PE of 32.3x sits above its own multi-year range observed in the historical data, which has frequently fluctuated between the high-teens and low-30s, suggesting the current valuation, while off recent highs, still embeds optimistic expectations relative to its own history, leaving limited room for multiple expansion.
PE
32.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Thermo Fisher's primary financial risk is its premium valuation (32.3x trailing P/E, 4.89x P/S), which makes the stock vulnerable to earnings misses or growth deceleration. A specific concern is the recent gross margin compression from 41.93% to 37.95% quarter-over-quarter; if this trend continues due to cost inflation or mix shift, it could jeopardize the path to the forward EPS of $36.24. While the balance sheet is strong (D/E 0.76), the company's growth-by-acquisition strategy carries integration and overpayment risks, especially in a higher interest rate environment that could increase financing costs for future deals.
Market & Competitive Risks: The stock faces significant valuation compression risk, as its multiples are elevated relative to both sector peers and its own history. With a beta of 0.97, it has market-like volatility but has experienced a -27.4% drawdown, indicating high idiosyncratic risk from its specific growth narrative unwinding. Competitive risks include pricing pressure in commoditized segments of the life sciences tools market and potential budget constraints in academic and government research funding, which could slow capital equipment sales. The stock's severe underperformance (-13% relative strength over 3 months) suggests it is already experiencing a sector de-rating.
Worst-Case Scenario: The worst-case scenario involves a 'growth scare' where Q1 2026 results show organic growth decelerating below 5% and gross margins failing to recover, triggering a wave of analyst downgrades and multiple compression. This could be exacerbated by a broader market sell-off. In this adverse scenario, the stock could re-test its 52-week low of $385.46, representing a downside of approximately -22% from the current price of $491.46. A break below that level could see a further decline towards the $350-$370 range, aligning with a forward P/E of 15x on lowered earnings estimates, for a total potential loss of 25-30%.